Federal and Florida regulators have rapidly narrowed the legal market for certain kratom products. The DEA has scheduled three alkaloids commonly associated with concentrated or synthetically derived kratom products, while Florida has adopted an additional rule governing 7-hydroxy and product composition.
For manufacturers, distributors, and retailers, this is no longer an issue that can be handled informally. Product-by-product testing, inventory review, labeling, certificates of analysis, and a documented compliance program are now essential.
How the Kratom Market Has Changed
Kratom has a long history as a botanical leaf product. Traditional products included whole leaves, teas, powders, capsules, and other forms using the plant more holistically. The modern market increasingly includes shots and pressed pills made with isolated or concentrated extracts rather than the whole plant.
That shift matters because kratom contains multiple naturally occurring alkaloids. 7-hydroxy has become especially prominent, and other alkaloids have been isolated or concentrated into products in ways that regulators view differently from trace amounts found in natural kratom.
The DEA Scheduled Three Kratom Alkaloids
The DEA scheduled three alkaloids often referred to as pseudo, MGM-15, and MGM-16. Although trace quantities may occur naturally, the agency’s action is aimed primarily at products containing larger amounts or synthetically derived versions.
The practical consequence is strict: a retail product containing any detectable amount of those scheduled compounds is treated as a Schedule I controlled substance. Handling Schedule I substances generally requires DEA registration, and ordinary kratom retailers will not have that authorization.
Retailers holding affected inventory should determine how to surrender it through an appropriate DEA diversion office or upstream distributor and preserve records showing that the inventory was properly removed from commerce.
The Federal 7-Hydroxy Decision Is Still Pending
The DEA separately proposed restrictions for 7-hydroxy above a specified threshold. That process remains open, with the comment period extended into September. As of the video’s recording, the agency had not issued a final federal limit for 7-hydroxy in kratom products.
Florida Adopted Stricter Kratom Standards
Florida initially issued extensive emergency rules addressing kratom compounds, labels, testing, and certificates of analysis. The state then rolled back much of that framework while waiting for federal action. After the DEA moved forward, Florida quickly issued a new rule that goes beyond the current federal position.
In Florida, a product containing 7-hydroxy becomes a Schedule I controlled substance if it exceeds one milligram per gram in a solid, exceeds one milligram per milliliter in a liquid, or fails to maintain at least 100 parts mitragynine for every one part 7-hydroxy by mass.
A SKU-by-SKU Kratom Compliance Review
Florida kratom businesses should review every SKU in three stages. First, determine whether the product contains any detectable amount of the three federally scheduled alkaloids. Second, determine whether its 7-hydroxy concentration exceeds the applicable one-milligram limit. Third, confirm that it satisfies the required 100-to-1 ratio of mitragynine to 7-hydroxy.
Products failing any of those tests cannot lawfully be manufactured, possessed, or sold in Florida. The state also imposed new labeling and certificate-of-analysis requirements. Existing products may receive additional time for some labeling changes, but there is no grace period for a product that qualifies as a controlled substance.
Kratom Businesses Need a Formal Compliance Program
The legal window for kratom products is becoming narrower and more technical. Businesses need reliable testing, compliant certificates of analysis, inventory controls, current labels, recall procedures, and a system for tracking both federal and state changes.
Failing to build that system can create both civil and criminal exposure. This article provides general educational information, not legal advice. Kratom businesses should work with qualified regulatory counsel to evaluate their products and operations.
